Niagara Falls, NY, Dec. 20, 2022 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging systems and clinical services company, is pleased to announce the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” Nuclear Imaging System.

A New Era in Nuclear Imaging

Positron Corporation has always been at the forefront of nuclear medicine technology, and their latest announcement marks yet another milestone in the field. The collaboration with Dr. Bober and Ochsner Health represents a significant step forward in the development of the new “Affinity PET-CT 4D” Nuclear Imaging System.

What is the “Affinity PET-CT 4D”?

This state-of-the-art imaging system combines positron emission tomography (PET) with computed tomography (CT) in 4 dimensions, allowing for unparalleled detail and accuracy in medical imaging. This new technology has the potential to revolutionize the way we diagnose and treat a wide range of medical conditions.

The clinical study conducted by Dr. Bober and Ochsner Health will play a crucial role in validating the effectiveness and safety of the “Affinity PET-CT 4D” system. The results of this study could have far-reaching implications for the future of nuclear imaging and healthcare as a whole.

Impact on Individuals

For individuals, the introduction of the “Affinity PET-CT 4D” system could mean faster and more accurate diagnosis of medical conditions, leading to better treatment outcomes and improved quality of life. This new technology has the potential to save lives and improve the overall patient experience.

Global Implications

On a global scale, the development of this new nuclear imaging system could revolutionize healthcare practices around the world. By providing healthcare professionals with more advanced tools for diagnosis and treatment, the “Affinity PET-CT 4D” has the potential to improve healthcare outcomes for millions of people worldwide.

Conclusion

The collaboration between Positron Corporation, Dr. Bober, and Ochsner Health represents a significant step forward in the field of nuclear imaging. The clinical study of the new “Affinity PET-CT 4D” system has the potential to revolutionize healthcare practices and improve outcomes for individuals around the world. This groundbreaking technology is poised to make a lasting impact on the future of healthcare.